Bristol's Tries Out New Selling Strategy With Yervoy Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Company details "new customer model" with an integrated reimbursement and medical support team that is being rolled out for the ipilimumab launch.
You may also be interested in...
Yervoy Off to Strong Start, Says BMS' Tony Hooper
The launch of Bristol's metastatic melanoma therapy is off to a strong start, but uncertainties linger, including whether the drug will compete with Roche's BRAF inhibitor.
Yervoy Off to Strong Start, Says BMS' Tony Hooper
The launch of Bristol's metastatic melanoma therapy is off to a strong start, but uncertainties linger, including whether the drug will compete with Roche's BRAF inhibitor.
As Yervoy Launch Nears, Pricing Of Maintenance Therapy Remains A Key Question
FDA’s approval of Bristol-Myers Squibb’s Yervoy (ipilimumab) for unresectable or metastatic melanoma March 25 grabbed attention for several reasons – the monoclonal antibody is the first new treatment approved for advanced melanoma in 13 years and the first ever to demonstrate a survival benefit.